Renoket Description

Each film-coated tablet contains: Calcium-4-methyl-2-oxo-valerate (α-ketoanalogue to leucine, calcium salt) 101 mg, calcium-3-methyl-2-oxo-butyrate (α-ketoanalogue to valine, calcium salt) 86 mg, calcium-2-oxo-3-phenylpropionate (α-ketoanalogue to phenylalanine, calcium salt) 68 mg, calcium-3-methyl-2-oxo-valerate (α-ketoanalogue to isoleucine, calcium salt) 67 mg, calcium-DL-2-hydroxy-4-(methylthio) butyrate (α-ketoanalogue to methionine, calcium salt) 59 mg, L-lysine acetate 105 mg, L-threonine 53 mg, L-histidine 38 mg, L-tyrosine 30 mg, L-tryptophan 23 mg.
Total nitrogen content/tablet: 36 mg. Calcium content/tablet: 1.25 mmol (equivalent to 50 mg).
Renoket contains all amino acids essential for uremic patients, 5 of them are keto- or hydroxyanalogues in the form of calcium salts. Therefore, it allows reduction in the nitrogen supply and provides calcium. It is a medication for the treatment of chronic kidney disease patients on conservative management therapy (CKD stage I, II, III). In combination with very low protein diet, it helps in delaying the progression of kidney disease in the predialysis period.